GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Cash, Cash Equivalents, Marketable Securities

XSpray Pharma AB (STU:6XP) Cash, Cash Equivalents, Marketable Securities : €6.59 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Cash, Cash Equivalents, Marketable Securities?

XSpray Pharma AB's quarterly cash, cash equivalents, marketable securities increased from Mar. 2024 (€9.20 Mil) to Jun. 2024 (€11.21 Mil) but then stayed the same from Jun. 2024 (€11.21 Mil) to Sep. 2024 (€6.59 Mil).

XSpray Pharma AB's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€26.47 Mil) to Dec. 2022 (€10.93 Mil) but then increased from Dec. 2022 (€10.93 Mil) to Dec. 2023 (€14.87 Mil).


XSpray Pharma AB Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for XSpray Pharma AB's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Cash, Cash Equivalents, Marketable Securities Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 20.03 32.00 26.47 10.93 14.87

XSpray Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.20 14.87 9.20 11.21 6.59

XSpray Pharma AB Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


XSpray Pharma AB  (STU:6XP) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


XSpray Pharma AB Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.

XSpray Pharma AB Headlines

No Headlines